Took position near $3 today.The bad market completely swamped the good news for POZN.Have traded these shares before, though not since the VIMOVO approval.The cloud that had been hanging here had been the TREXIMET litigation. That's over, and POZN won.Their patents protected them, now thru 2017 and beyond. This ensures the vital cash flow near term needed to allow them to advance PA on their own, as an independent entity.Any other day, and shares would have been pushing closer to $4 than $3. Worth buying, imo.
I was expecting it to go up, even today. It's a steal here at <$100M market cap. Treximet alone is worth that (6 years x $16M/YR). It does make sense for GSK to snatch it up here. Make an offer at $6, they would basically get Vimovo royalties and PA for $30M.
Good new indeed my friend. But the market will push this even lower. Be ready to buy more. When the dust settles, this should move back over $5 fairly quick.